IC-MPGN
Clinical trials for IC-MPGN explained in plain language.
Never miss a new study
Get alerted when new IC-MPGN trials appear
Sign up with your email to follow new studies for IC-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a new drug, iptacopan, for people with a rare kidney disease called IC-MPGN. The goal is to see if the drug can reduce protein in the urine and help protect kidney function. About 106 adults and teens will take either iptacopan or a placebo for up to 18 months. T…
Matched conditions: IC-MPGN
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:57 UTC
-
New drug trial offers hope for kidney disease patients
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys. The goal is to see if the drug is safe and can help control the disease. Some participants will get ADX-038 alone, and others will get it with a…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:56 UTC
-
New drug ADX-038 aims to control kidney disease in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system, such as IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disease and be on…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC